MRK Merck & Co., Inc.

NYSE merck.com


$ 83.85 $ -0.53 (-0.63 %)    

Wednesday, 15-Oct-2025 12:58:57 EDT
QQQ $ 601.88 $ -1.94 (-0.32 %)
DIA $ 463.27 $ -1.37 (-0.29 %)
SPY $ 664.37 $ -2.42 (-0.36 %)
TLT $ 90.75 $ -0.21 (-0.23 %)
GLD $ 386.39 $ 0.43 (0.11 %)
$ 84.7
$ 84.22
$ 83.83 x 4
$ 83.86 x 140
$ 83.67 - $ 84.68
$ 71.87 - $ 107.60
9,675,036
na
211.56B
$ 0.27
$ 12.90
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-02-2025 03-31-2025 10-Q
3 02-25-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 05-03-2024 03-31-2024 10-Q
7 02-26-2024 12-31-2023 10-K
8 11-03-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-05-2023 03-31-2023 10-Q
11 02-24-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-25-2022 12-31-2021 10-K
16 11-05-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-06-2020 03-31-2020 10-Q
23 02-26-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 02-27-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-08-2018 03-31-2018 10-Q
31 02-27-2018 12-31-2017 10-K
32 11-07-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 02-28-2017 12-31-2016 10-K
36 11-07-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 02-26-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mercks-new-hiv-treatment-works-as-well-as-top-drug-in-late-trials

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase ...

 merck-shares-additional-data-from-the-phase-3-studies-of-two-drug-regimen-of-doravirineislatravir-for-hiv-1-infection-that-was-virologically-suppressed-on-bictegraviremtricitabinetenofovir-alafenamidei-in-trial-mk-8591a-052-or-antiretroviral-therapy-in-trial-mk-8591a-051

n trial MK-8591A-052, adults living with virally suppressed HIV-1 infection who switched to DOR/ISL from BIC/FTC/TAF showed min...

 hedge-fund-shah-capital-urges-novavax-to-consider-sale-amid-vaccine-rollout-struggles-sees-5-billion-potential

Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least...

 citigroup-reinstates-neutral-on-merck--co-raises-price-target-to-95

Citigroup analyst Geoff Meacham reinstates Merck & Co (NYSE:MRK) with a Neutral and raises the price target from $84 to ...

 uk-weighs-25-rise-in-drug-prices-as-pharma-giants-pause-investments

UK ministers consider raising NHS drug spending by up to 25% amid pharma investment delays and pressure from US pricing policies.

 merck-to-present-hiv-treatment-data-at-20th-european-aids-conference-in-paris

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that it will present new findings from ...

 merck-to-unveil-cancer-treatment-data-at-esmo-2025-featuring-key-studies-on-keytruda-and-new-antibody-drug-conjugates

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstrac...

 merck-doctors-reject-proposal-to-break-up-combined-mmr-vaccine

Merck and health experts push back against U.S. officials' call to split the MMR vaccine, warning it could delay immunizati...

 vaccine-maker-merck-says-there-is-no-published-scientific-evidence-that-shows-any-benefit-in-separating-the-combination-mmr-vaccine-into-three-individual-shots-there-are-no-approved-us-monovalent-measles-mumps-and-rubella-single-antigen-vaccines

-Reuters

 merck-initiates-three-phase-2b-trials-evaluating-safety-and-efficacy-of-tulisokibart-in-patients-with-three-immune-mediated-inflammatory-diseases

Tulisokibart, an investigational anti-TL1A monoclonal antibody currently in Phase 3 trials for ulcerative colitis and Crohn'...

 wall-street-hits-record-highs-as-rate-cut-bets-offset-shutdown-this-week-in-markets

S&P500, Nasdaq100, Dow Jones, and Russell 2000 all hit record highs as investors focus on corporate optimism, monetary easi...

 these-3-pharma-stocks-are-rallying--and-still-trade-absurdly-cheap

Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.

 merck-animal-healths-bravecto-quantum-once-yearly-flea-and-tick-injection-approved-by-health-canada

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., R...

 trump-pfizer-deal-pushes-health-care-stocks-to-best-rally-in-5-years

Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tari...

 health-care-stocks-rally-nike-beats-the-street-whats-moving-markets-wednesday

Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps m...

 mercks-winrevair-cuts-clinical-worsening-risk-by-76-among-hypertension-patients

Merck reported Phase 3 results showing Winrevair significantly reduced clinical worsening in pulmonary arterial hypertension pa...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION